Kite, a Gilead company, announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of two years after a single infusion of Yescarta (median follow up of 27.1 months), 39 percent of patients were in an ongoing response.
Kite announces two-year data for Yescarta in patients with refractory large B-cell lymphoma
YOU MAY BE INTERESTED IN
The National Coalition for Cancer Survivorship has provided the Cancer History Project with a rich archive of its newsletters: the NCCS Networker, volumes 1-11.